| Literature DB >> 31461642 |
Li-Fang Chu1, Daniel Mamott2, Zijian Ni3, Rhonda Bacher4, Cathy Liu2, Scott Swanson2, Christina Kendziorski5, Ron Stewart2, James A Thomson6.
Abstract
Defects in somitogenesis result in vertebral malformations at birth known as spondylocostal dysostosis (SCDO). Somites are formed with a species-specific periodicity controlled by the "segmentation clock," which comprises a group of oscillatory genes in the presomitic mesoderm. Here, we report that a segmentation clock model derived from human embryonic stem cells shows many hallmarks of the mammalian segmentation clock in vivo, including a dependence on the NOTCH and WNT signaling pathways. The gene expression oscillations are highly synchronized, displaying a periodicity specific to the human clock. Introduction of a point of mutation into HES7, a specific mutation previously associated with clinical SCDO, eliminated clock gene oscillations, successfully reproducing the defects in the segmentation clock. Thus, we provide a model for studying the previously inaccessible human segmentation clock to better understand the mechanisms contributing to congenital skeletal defects.Entities:
Keywords: HES7; gene oscillation; human embryonic stem cells; segmentation clock; spondylocostal dysostosis
Year: 2019 PMID: 31461642 PMCID: PMC6814198 DOI: 10.1016/j.celrep.2019.07.090
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423
Figure 1.Human ESC Differentiation to PSM and Somite Cell States
(A) Schematic of differentiation strategy of human ESCs differentiation toward mesendoderm, PSM, and somite cell states. Immunofluorescence co-staining for POU5F1, T, TBX6, and MEOX1 for characterization of the differentiation protocol. All scale bars represent 100 μm.
(B) Heatmap of RNA-seq data of the somite differentiation. Triplicate samples are shown for each time point. Selected markers are provided to represent the ESC, mesendoderm, PSM, and somite cell states.
(C) PCA of RNA-seq data collected every 30 min for the first 12 h after switching from PSM medium to somite medium. Each time point is collected in duplicates and are indicated by the color key.
(D) Heatmap of selected marker gene expression from the experiment in (C), representing PSM, somitogenesis (blue font), and somite cell states. All expression values (normalized expect counts [nECs]) are scaled minimum to maximum expression per gene row, indicated as a horizontal bar.
Figure 2.Detection and Quantification of HES7 Oscillation
(A) Schematic of knock-in HES7-NLuc-2A-tdTomato-PGK-NEO cassette to the endogenous HES7 locus. The arrow indicates the position of the SpCas9/guide RNA (gRNA) cut site. Grey boxes indicate the exons. The lower panel shows analysis by flow cytometry of HES7-reporter expression during the differentiation from human ESCs to PSM cells. The y axis indicates the tdTomato detection channel. The x axis indicates the GFP channel.
(B) Upper left panel: a schematic of the experimental strategy to measure HES7 oscillation in PSM medium. Three subpanels indicated the cell density for differentiation to measure gene oscillation. The y axis indicates the luminescence signals (scaled from minimum to maximum from representative samples in arbitrary units [a.u.]). The x axis indicates 32 h of live cell luminescence detection.
(C) Upper panel: a schematic of the quantification of peak-to-peak (blue) and valley-to-valley (red) periodicity. The lower panel shows the quantification results. The y axis indicates minutes. The x axis indicates quantifications from the first to the fourth peaks.
(D) Left panel: an example frame of NLuc luminescence imaging experiments. Overlay shows the locations of 25 regions of interest (ROIs) indicated as white boxes. Right panel: the quantification results of 25 ROIs over 20 h of time-lapse imaging. The y axis indicates the luminescence signals (scaled from minimum to maximum from representative samples in a.u.). The time-lapse video is shown as Video S2. Insert shows the corresponding bright field cell image. All scale bars represent 100 μm.
Figure 3.Characterization of HES7 Oscillation and Modeling SCDO4 with Genome Editing
(A) The impact of modulating NOTCH signaling pathways on HES7 oscillation. Left panel: DAPT treatment (magenta). Middle panel: inducible NICD transgene expression (blue). Right panel: inducible HES7 transgene expression (green). The controls are shown in black. Blue arrowhead indicates when the NLuc luciferin and small molecules or DOX were applied. All luminescence oscillation data presented is scaled from minimum to maximum signal and shown as mean ± SEM (shaded area), obtained from 4 to 5 replicates in each experiment.
(B) A schematic for measuring the propagation of HES7 oscillation. The lower panels show the comparison between PSM medium (black) and with base medium supplemented with A83-01 and CHIR (yellow) only. Right panel: PSM medium (black) compared with only withdrawal of A83-01 (green) or the withdrawal of CHIR (magenta).
(C) Strategy for genome editing to introduce a R25W substitution. The sequences for gRNA protospacer adjacent motif (PAM) domain (magenta) and targeted sequences (blue) are indicated. The codon to be mutated is underlined, CGG (Arg) to TGG (Trp). Right panel: Sanger sequencing results of the parental line (wild type [WT]) and a homozygous R25W clone.
(D) Representative oscillation profile of WT (black) overlay with a R25W clone (red). Right panel: quantification of HES7 expression level between WT and R25W clones. ****p < 0.0001, Student’s t test. Data presented as the mean ± SD.
(E) A proposed working model of human segmentation clock and HES7 oscillation. NOTCH signaling is upstream of HES7 activation and oscillation. During the transition from mesendoderm to PSM state, WNT/β-catenin signaling activation and TGF-β signaling inhibition are crucial to propagate HES7 oscillation. Luminescence is measured in arbitrary units (a.u.).
KEY RESOURCES TABLE
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Antibodies | ||
| Anti-POU5F1 | Santa Cruz | Sc-5279; RRID: AB_628051 |
| Anti-T (Brachyury) (APC-conjugated) | R&D Systems | IC2085A; RRID: AB_2271455 |
| Anti-TBX6 | R&D Systems | AF4744; RRID: AB_2200834 |
| Anti-MEOX1 | Atlas Antibodies | HPA045214; RRID: AB_10959299 |
| Chicken anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 594 | Thermo Fisher Scientific | A-21201; RRID: AB_2535787 |
| Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 350 | Thermo Fisher Scientific | A-21081; RRID: AB_2535738 |
| Chicken anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 | Thermo Fisher Scientific | A-21441; RRID: AB_2535859 |
| Chemicals, Peptides, and Recombinant Proteins | ||
| CHIR 99021 | Tocris | 4423 |
| A 83-01 | Tocris | 2939 |
| DAPT | Tocris | 2634 |
| endo-IWR1 | Tocris | 3532 |
| XAV 939 | Tocris | 3748 |
| (+)-JQ1 | Tocris | 4499 |
| 10058-F4 | Tocris | 4406 |
| Y-27632 dihydrochloride | Tocris | 1254 |
| RepSox | Tocris | 3742 |
| SB 431542 | Tocris | 1614 |
| Recombinant Human Noggin Protein | R&D Systems | 6057-NG-01M/CF |
| Recombinant Human TGF-beta 1 Protein, CF | R&D Systems | 240-B/CF |
| Human Holo-Transferrin Protein, CF | R&D Systems | 2914-HT |
| Porcn Inhibitor II, C59 | Sigma-Aldrich | 5004960001 |
| Insulin solution human | Sigma-Aldrich | I9278 |
| Doxycycline hyclate | Sigma-Aldrich | D9891 |
| BD Matrigel Matrix Growth Factor Reduced | BD Biosciences | 354230 |
| UltraPure 0.5M EDTA, pH 8.0 | Thermo Fisher Scientific | 15575020 |
| Dulbecco’s phosphate-buffered saline (DPBS) | Thermo Fisher Scientific | 14190250 |
| DMEM/F-12 | Thermo Fisher Scientific | 11320082 |
| StemPro Accutase Cell Dissociation Reagent | Thermo Fisher Scientific | A1110501 |
| TrueCut Cas9 Protein v2 | Thermo Fisher Scientific | A36497 |
| Critical Commercial Assays | ||
| GeneArt Precision gRNA Synthesis Kit | Thermo Fisher Scientific | A29377 |
| GeneArt Genomic Cleavage Detection Kit | Thermo Fisher Scientific | A24372 |
| POU5F1 TaqMan Assay (4331182) | Thermo Fisher Scientific | Hs00999634_gH |
| TBX6 TaqMan Assay (4331182) | Thermo Fisher Scientific | Hs00365539_m1 |
| HES7 TaqMan Assay (4331182) | Thermo Fisher Scientific | Hs03988571_m1 |
| LFNG TaqMan Assay (4331182) | Thermo Fisher Scientific | Hs00385436_g1 |
| DLL1 TaqMan Assay (4331182) | Thermo Fisher Scientific | Hs00194509_m1 |
| MEOX1 TaqMan Assay (4331182) | Thermo Fisher Scientific | Hs00244943_m1 |
| FOXC2 TaqMan Assay (4331182) | Thermo Fisher Scientific | Hs00270951_s1 |
| MSGN1 TaqMan Assay (4331182) | Thermo Fisher Scientific | Hs03405514_s1 |
| GAPDH TaqMan Assay (VIC_PL, 4448486) | Thermo Fisher Scientific | Hs02786624_g1 |
| Nano-Glo(R) Live Cell EX-6829 | Promega | CS2025A03 |
| Deposited Data | ||
| Raw RNA-seq data | This paper | GEO: GSE128469 |
| Experimental Models: Cell Lines | ||
| Human: WA01 (H1) hESC line (NIH approval number NIHhESC-10-0043) | WiCell | WA01: H1 Human ES |
| Oligonucleotides | ||
| HES7 knockin junction PCR, in | This paper | Synthesized from IDT |
| HES7 for Southern blotting probe template, in | This paper | Synthesized from IDT |
| Primers for make HES7-C73T-gRNA template, in | This paper | Synthesized from IDT |
| Oligo for HES7-C73T-ssODN donor, in | This paper | Synthesized from IDT |
| Primers for sequencing HES7 Exon2, in | This paper | Synthesized from IDT |
| Recombinant DNA | ||
| HES7-NLuc-2A-tdTomato knockin vector | This paper | Addgene, 130932 |
| pCRII-Blunt-U6-HES7-STOP-gRNA | This paper | Addgene, 130933 |
| pB-TAG-NICD | This paper | Addgene, 130934 |
| pB-TAG-HES7 | This paper | Addgene, 130935 |
| pB-EF1a-NLuc | This paper | Addgene, 130936 |
| NanoLuc gene cassette | Promega | GeneBank: JQ437370 |
| Software and Algorithms | ||
| Bandpass and detrending Perl code | This paper | |
| Wave-Crest | ||
| Trendy | ||
| Enrichr | ||
| Other | ||
| scRNA-seq data for somitomere cells | ||